Table 1 The clinicopathological characteristics, surgical data of IM neoadjuvant therapy and direct surgery for all 101 rectal GIST patients
Variables | IM neoadjuvant therapy (N = 31) | Direct surgery (N = 70) | Number (N = 101) (N/%) |
|---|---|---|---|
Agea (years) | |||
≤ 60 | 17 | 45 | 62 (61.4) |
> 60 | 14 | 25 | 39 (38.6) |
Sex | |||
Male | 17 | 47 | 64 (63.4) |
Female | 14 | 23 | 37 (36.6) |
Different era | |||
2002–2011 | 0 | 22 | 22 (21.8) |
2012–2020 | 31 | 48 | 79 (78.2) |
ECOG performance score | |||
0 | 29 | 62 | 91 (90.1) |
1 | 2 | 8 | 10 (9.9) |
Initial clinical manifestation | |||
Rectal bleeding | 10 | 10 | 20 (19.8) |
Change in bowel of stool | 4 | 11 | 15 (14.9) |
Change in bowel habit | 5 | 13 | 18 (17.8) |
Rectal discomfort | 5 | 12 | 17 (16.8) |
Digital rectal examinationb | 3 | 15 | 18 (17.8) |
Others | 4 | 9 | 13 (12.9) |
Tumor sizec (cm) | |||
≤ 5 | 2 | 34 | 36 (35.6) |
> 5 | 29 | 36 | 65 (64.4) |
Approach of surgery | |||
Laparotomy | 25 | 57 | 82 (81.2) |
Laparoscopy | 6 | 8 | 14 (13.9) |
Endoscopy | 0 | 5 | 5 (4.9) |
Type of surgery | |||
Local | 30 | 65 | 95 (94.1) |
Radical | 1 | 5 | 6 (5.9) |
Procedure of surgeryd | |||
LAR | 27 | 43 | 70 (69.3) |
ISR | 2 | 7 | 9 (9.0) |
APR | 2 | 15 | 17 (16.8) |
LR | 0 | 5 | 5 (4.9) |
Covering stoma in sphincter-preserving surgery (LAR + ISR)e | |||
Yes | 3 | 10 | 13 (16.5) |
No | 26 | 40 | 66 (83.5) |
Surgical margin | |||
Positive | 0 | 4 | 4 (4.0) |
Negative | 31 | 66 | 97 (96.0) |
Tumor rupture | |||
Yes | 0 | 0 | 0 (0.0) |
No | 31 | 70 | 101 (100.0) |
Postoperative complications | |||
Rectal bleeding | 0 | 1 | 1 (1.0) |
Anastomotic fistula | 1 | 4 | 5 (4.9) |
Wound infection | 2 | 4 | 6 (5.9) |
Abdominal infection | 1 | 2 | 3 (3.0) |
Others | 1 | 4 | 5 (4.9) |
None | 26 | 55 | 81 (80.3) |
Mitotic index (50HPF) | |||
≤ 5 | 22 | 28 | 50 (49.5) |
> 5 | 9 | 42 | 51 (50.5) |
Pathological feature | |||
Spindle | 28 | 54 | 82 (81.2) |
Epithelial | 2 | 13 | 15 (14.9) |
Mixed | 1 | 3 | 4 (3.9) |
Immunohistochemistry | |||
CD117 positive | 29 | 69 | 98 (97.0) |
DOG-1positivef | 29 | 46 | 75 (96.2) |
CD34 positive | 28 | 55 | 83 (82.1) |
Modified NIH criteriag | |||
Very low risk | – | 8 | 8 (11.4) |
Low risk | – | 10 | 10 (14.3) |
Intermediate risk | – | 7 | 7 (10.0) |
High risk | – | 45 | 45 (64.3) |
Genetic mutationh | |||
KIT Exon 11 mutation | 14 | 25 | 39 (83.0) |
KIT Exon 9 mutation | 2 | 2 | 4 (8.5) |
Wild type mutation | 1 | 3 | 4 (8.5) |
Postoperative IM adjuvant treatment | |||
Yes | 25 | 24 | 49 (48.5) |
No | 6 | 46 | 52 (51.5) |